Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 6/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 4/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17785657 | 0.79 | CREBBP (0.47) | CREBBPBRD4EP300 | |
| SCHEMBL17795493 | 0.76 | CREBBP (0.39) | CREBBPBRD4EP300 | |
| SCHEMBL17785674 | 0.74 | AR (0.32) | ARP4HB | |
| SCHEMBL17809750 | 0.74 | CREBBP (0.44) | CREBBPBRD4EP300 | |
| SCHEMBL17785618 | 0.74 | CYP11B2 (0.48) | CYP11B2CREBBPBRD4 | |
| SCHEMBL17806369 | 0.73 | CREBBP (0.37) | CREBBPBRD4EP300 | |
| SCHEMBL19368863 | 0.72 | CREBBP (0.39) | CREBBPBRD4EP300 | |
| SCHEMBL17785637 | 0.72 | CREBBP (0.50) | CREBBPBRD4EP300 | |
| SCHEMBL29403112 | 0.72 | CREBBP (0.50) | CREBBPBRD4EP300 | |
| SCHEMBL17806365 | 0.71 | CREBBP (0.42) | CREBBPBRD4EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016086200-A1 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-02 | — | — | WO | disclosed |